BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38586917)

  • 1. Engineering lauric acid-based nanodrug delivery systems for restoring chemosensitivity and improving biocompatibility of 5-FU and OxPt against
    Su M; Wen X; Yu Y; Li N; Li X; Qu X; Elsabahy M; Gao H
    J Mater Chem B; 2024 Apr; 12(16):3947-3958. PubMed ID: 38586917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphiphilic polymeric nanodrug integrated with superparamagnetic iron oxide nanoparticles for synergistic antibacterial and antitumor therapy of colorectal cancer.
    Li X; Niu J; Deng L; Yu Y; Zhang L; Chen Q; Zhao J; Wang B; Gao H
    Acta Biomater; 2024 Jan; 173():432-441. PubMed ID: 37984629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
    Narayan S; Ramisetti S; Jaiswal AS; Law BK; Singh-Pillay A; Singh P; Amin S; Sharma AK
    Eur J Med Chem; 2019 Jan; 161():456-467. PubMed ID: 30384048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fusobacterium nucleatum promotes chemoresistance to 5-fluorouracil by upregulation of BIRC3 expression in colorectal cancer.
    Zhang S; Yang Y; Weng W; Guo B; Cai G; Ma Y; Cai S
    J Exp Clin Cancer Res; 2019 Jan; 38(1):14. PubMed ID: 30630498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exosomes secreted by Fusobacterium nucleatum-infected colon cancer cells transmit resistance to oxaliplatin and 5-FU by delivering hsa_circ_0004085.
    Hui B; Zhou C; Xu Y; Wang R; Dong Y; Zhou Y; Ding J; Zhang X; Xu J; Gu Y
    J Nanobiotechnology; 2024 Feb; 22(1):62. PubMed ID: 38360615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remotely Controllable Supramolecular Nanomedicine for Drug-Resistant Colorectal Cancer Therapy Caused by Fusobacterium nucleatum.
    Yan X; Xin Y; Yu Y; Li X; Li B; Elsabahy M; Zhang J; Ma F; Gao H
    Small Methods; 2024 Mar; 8(3):e2301309. PubMed ID: 38018349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy.
    Qu CY; Zhou M; Chen YW; Chen MM; Shen F; Xu LM
    Int J Nanomedicine; 2015; 10():3911-20. PubMed ID: 26089667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cancer chemotherapeutic 5-fluorouracil is a potent Fusobacterium nucleatum inhibitor and its activity is modified by intratumoral microbiota.
    LaCourse KD; Zepeda-Rivera M; Kempchinsky AG; Baryiames A; Minot SS; Johnston CD; Bullman S
    Cell Rep; 2022 Nov; 41(7):111625. PubMed ID: 36384132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Targeting Nanoassembly for Enhanced Colorectal Cancer Therapy by Eliminating Intratumoral
    Li X; Ma Y; Xin Y; Ma F; Gao H
    ACS Appl Mater Interfaces; 2023 Mar; ():. PubMed ID: 36916659
    [No Abstract]   [Full Text] [Related]  

  • 10. Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma.
    Ning Q; Liu YF; Ye PJ; Gao P; Li ZP; Tang SY; He DX; Tang SS; Wei H; Yu CY
    ACS Appl Mater Interfaces; 2019 Mar; 11(11):10578-10588. PubMed ID: 30802029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A polymeric prodrug of 5-fluorouracil-1-acetic acid using a multi-hydroxyl polyethylene glycol derivative as the drug carrier.
    Li M; Liang Z; Sun X; Gong T; Zhang Z
    PLoS One; 2014; 9(11):e112888. PubMed ID: 25389968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Andrographolide enhanced 5-fluorouracil-induced antitumor effect in colorectal cancer via inhibition of c-MET pathway.
    Su M; Qin B; Liu F; Chen Y; Zhang R
    Drug Des Devel Ther; 2017; 11():3333-3341. PubMed ID: 29200829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudolaric acid B induces mitotic arrest and apoptosis in both 5-fluorouracil-sensitive and -resistant colorectal cancer cells.
    Wen C; Chen J; Zhang D; Wang H; Che J; Qin Q; He L; Cai Z; Lin M; Lou Q; Huang L; Chen D; Iwamoto A; Ren D; Wang L; Lan P; Wang J; Liu H; Yang X
    Cancer Lett; 2016 Dec; 383(2):295-308. PubMed ID: 27713084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer.
    Liu T; Zhang X; Du L; Wang Y; Liu X; Tian H; Wang L; Li P; Zhao Y; Duan W; Xie Y; Sun Z; Wang C
    Mol Cancer; 2019 Mar; 18(1):43. PubMed ID: 30890168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
    Luo D; Zhang Y; Yang S; Tian X; Lv Y; Guo Z; Liu X; Han G; Liu S; Wang W; Cui S; Qu X; Wan S
    Eur J Med Chem; 2021 Dec; 225():113775. PubMed ID: 34411894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Watson-Crick G[triple bond, length as m-dash]C"-inspired supramolecular nanodrug of methotrexate and 5-fluorouracil for tumor microenvironment-activatable self-recognizing synergistic chemotherapy.
    Chen M; Chen S; Zhu F; Wang F; Tian H; Fan Z; Ke S; Hou Z; Li Y
    J Mater Chem B; 2020 May; 8(17):3829-3841. PubMed ID: 32232285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel octapeptide-DTX prodrugs targeting MMP-7 as effective agents for the treatment of colorectal cancer with lower systemic toxicity.
    Liu ZY; Tang ML; Ning JF; Hao YP; Zhou L; Sun X
    Eur J Med Chem; 2020 May; 193():112194. PubMed ID: 32203786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-Delivery Janus-Prodrug for Precise Immuno-Chemotherapy of Colitis-Associated Colorectal Cancer.
    Zhang Q; Li S; Bai L; Yu D; Li H; Tong R
    ACS Appl Mater Interfaces; 2022 Jan; 14(1):297-306. PubMed ID: 34958191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thermosensitive methyl-cellulose-based injectable hydrogel carrying oxaliplatin for the treatment of peritoneal metastasis in colorectal cancer.
    Yang J; Wei Y; Gao L; Li Z; Yang X
    J Mater Chem B; 2024 May; 12(21):5171-5180. PubMed ID: 38687592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual drug loaded liposome bearing apigenin and 5-Fluorouracil for synergistic therapeutic efficacy in colorectal cancer.
    Sen K; Banerjee S; Mandal M
    Colloids Surf B Biointerfaces; 2019 Aug; 180():9-22. PubMed ID: 31015105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.